The PE Ratio as of December 2024 (TTM) for Design Therapeutics, Inc. (DSGN) is -7.31

According to Design Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.31. This represents a change of 62.53% compared to the average of -4.50 of the last 4 quarters.

Design Therapeutics, Inc. (DSGN) Historical PE Ratio (quarterly & annually)

How has DSGN PE Ratio performed in the past?

The mean historical PE Ratio of Design Therapeutics, Inc. over the last ten years is -145.40. The current -7.31 PE Ratio has changed 402.75% with respect to the historical average. Over the past ten years (40 quarters), DSGN's PE Ratio was at its highest in in the September 2023 quarter at -2.09. The PE Ratio was at its lowest in in the March 2020 quarter at -425.43.

Design Therapeutics, Inc. (DSGN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Design Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Design Therapeutics, Inc. (DSGN) Average PE Ratio

How has DSGN PE Ratio performed in the past?

The current PE Ratio of Design Therapeutics, Inc. (DSGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Design Therapeutics, Inc. (DSGN) PE Ratio vs. Peers

How is DSGN’s PE Ratio compared to its peers?

Design Therapeutics, Inc.’s PE Ratio is less than Monte Rosa Therapeutics, Inc. (-4.90), less than Werewolf Therapeutics, Inc. (-1.10), less than Ikena Oncology, Inc. (-1.35), less than Stoke Therapeutics, Inc. (-6.20), less than Achilles Therapeutics plc (-0.59), less than Neoleukin Therapeutics, Inc. (-5.86), less than Magenta Therapeutics, Inc. (-0.15), less than Graphite Bio, Inc. (-0.13), less than ALX Oncology Holdings Inc. (-0.65), less than Aadi Bioscience, Inc. (-1.25), less than ADC Therapeutics SA (-0.98), less than AlloVir, Inc. (-0.52), greater than Gracell Biotechnologies Inc. (-29.25), less than Theseus Pharmaceuticals, Inc. (-6.29), less than Erasca, Inc. (-4.40), less than Cullinan Oncology, Inc. (-4.82), greater than Immunocore Holdings plc (-26.20), less than C4 Therapeutics, Inc. (-2.68),

Build a custom stock screener for Design Therapeutics, Inc. (DSGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Design Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Design Therapeutics, Inc. (DSGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Design Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.